PEN — Penumbra Inc
NYSE · Health Care · Health Care
- Latest Close
- $332.21
- 30-Day Move
- +6.7%
- Market Cap
- $13.2B
- Shares Outstanding
- 39,240,000
- P/E Ratio
- 74.27
- P/B Ratio
- 8.53
Analyst consensus: Buy · 22 analysts
Penumbra Inc
A read-only Alphactor snapshot forPenumbra Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-22
Topline snapshot
Latest Close
$332.21
30-Day Move
+6.7%
Market Cap
$13.2B
Shares Outstanding
39,240,000
P/E Ratio
74.27
P/B Ratio
8.53
$332.21
+6.7%last 90 delayed daily bars
90D High
$362.41
90D Low
$290.00
Avg Volume
863,988
Gross margin is running at 67.1%, which gives a quick read on operating quality before you open the full model.
Net margin is 12.7%, useful for comparing PEN against peers in Health Care.
PEN is up 6.7% over the last 30 trading days shown on this page.
Latest operating income is $59M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$113.61
Rule of 40
30.0%
Dark Pool Short %
68.2%
Latest Close
$332.21
30-Day Move
+6.7%
Market Cap
$13.2B
Shares Outstanding
39,240,000
P/E Ratio
74.27
P/B Ratio
8.53
ROE
12.4%
ROA
9.7%
Gross Margin
67.1%
Operating Margin
13.5%
Net Margin
12.7%
Debt / Equity
0.02
Current Ratio
6.64
Latest Revenue
$385M
Revenue
$385M
Gross Profit
$262M
Operating Income
$59M
Net Income
$47M
Gross Margin
6714.0%
Net Margin
1266.0%
Current Ratio
6.64
Debt / Equity
0.02
Fair Value
$113.61
Upside / Downside
-65.8%
Signal
Overvalued
Implied Growth
22.6%
DCF
$138.35
EPV
$24.47
EV/Rev
$178.02
Growth Assumption
18.3%
Discount Rate
8.4%
Terminal Growth
2.0%
Base FCF
$175M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
High growth priced in
Altman Z
21.82
Safe
Piotroski
8
Strong (7-9)
Cash Conversion
1.34x
Rule of 40
30.0%
Acceptable
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $847M | $6M | $-2M | $-75M |
| 2023-12-31 | $1.1B | $92M | $91M | $82M |
| 2024-12-31 | $1.2B | $86M | $14M | $147M |
| 2025-12-31 | $1.4B | $189M | $178M | $175M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$0
Sell Value
$16M
Buys
0
Sells
58
Buy Value
$0
Sell Value
$16M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-02 | Grewal Harpreet | Sell | 100 | $328.22 |
| 2026-03-15 | Narayan Shruthi | F | 117 | $336.18 |
| 2026-03-15 | Shiu Lambert | F | 150 | $336.18 |
| 2026-03-15 | Yuen Maggie | F | 186 | $336.18 |
| 2026-03-15 | Roberts Johanna | F | 186 | $336.18 |
| 2026-03-02 | Yuen Maggie | Sell | 2,432 | $342.30 |
| 2026-02-17 | Narayan Shruthi | A | 2,630 | $0.00 |
| 2026-02-17 | Shiu Lambert | A | 2,300 | $0.00 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 1,265,034 | 0.03% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1,167,350 | 0.03% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 844,196 | 0.02% | 2025-12-31 |
| T. Rowe Price Health Sciences Fund, Inc. | 536,111 | 0.01% | 2025-12-31 |
| VANGUARD WORLD FUND-Vanguard U.S. Growth Fund | 502,939 | 0.01% | 2025-11-30 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 476,212 | 0.01% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 422,066 | 0.01% | 2025-12-31 |
| SmallCap World Fund Inc | 412,644 | 0.01% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Two Sigma Advisers
Filed 2025-11-14
--
--
FMR LLC (Fidelity)
Filed 2026-02-17
$1.6B
-12.9%
Vanguard Group
Filed 2026-01-29
$1.2B
-1.7%
BlackRock
Filed 2024-05-10
$906M
--
Citadel Advisors
Filed 2026-02-17
$308M
--
Geode Capital Management
Filed 2026-02-09
$238M
+2.5%
3.5
Consensus
Buy—
—
—
22
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.